1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

Authors :: K. Park
S.S. Ramalingam
Juergen Wolf
Hossein Borghaei
H. Yang
Carlos H. Barrios
G. Goss
Enriqueta Felip
Martin Reck
Benjamin Besse
Koichi Goto
Alexander I. Spira
C. Obiozor
Frank Griesinger
Michael Boyer
Ferdinandos Skoulidis
Source :: Annals of Oncology. 31:S894-S895
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: business.industry
non-small cell lung cancer (NSCLC)
Hematology
medicine.disease
medicine.disease_cause
Oncology
Docetaxel
Multicenter study
Mutation (genetic algorithm)
Cancer research
Medicine
In patient
KRAS
business
Previously treated
medicine.drug

Full Text Access

Tools